Fortis Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://fortistx.com
A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1
Completed
- Conditions
- Multiple MyelomaMultiple Myeloma With Failed RemissionMultiple Myeloma in Relapse
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Fortis Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03650491
- Locations
- 🇺🇸
Icahn School of Medicine at Mt. Sinai, New York, New York, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Fortis Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03575819
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath